MAP1B and fragile X syndrome: In fact, we demonstrate that both the genetic reduction of MAP1B by shRNA knockdown and the treatment with rapamycin could rescue morphological and electrophysiological deficits of FXS and 5q13.2trip ASD patient-derived neurons.